Comparing the Efficacy of Viable Cryopreserved Placental Membrane for the Treatment of Wounds of Diverse Etiologies

Abstract

INTRODUCTION AND OBJECTIVES: The benefits of using amniotic tissue in skin regeneration are well documented. Today, cryopreservation technology allows for better availability and maintenance of mesenchymal stem cells. This is of particular interest in treating the diabetic foot ulcer as this population has fewer mesenchymal stem cells. The objective of this case series investigation was to compare the efficacy of cryopreserved human amniotic stem cells in treating foot wounds of different etiologies. We will present data and case photos for a diabetic foot ulcer, venous leg ulcer, arterial ankle ulcer, and a pyoderma gangrenosum ulcer METHODS: Cryopreserved human amniotic stem cell grafts were applied to patients with chronic ulcers of different etiologies that had been subjected to at least 4 weeks of standard wound care and did not show adequate clinical progress. Wound area was recorded and photographed on weekly basis. Area reduction was charted over time and the results of each individual case were compared to one another. RESULTS: All ulcers displayed results that well exceeded the established parameters of weekly healing rates for effective wound treatment modalities. • Pyoderma gangrenosum displayed the poorest response to treatment. However, it is worth noting that the patient was not compliant in the prescribed adjunctive treatment regimen but managed to achieve 64% wound reduction. • All ulcers showed the largest appreciable amount of healing in both total area reduction and week-to- week closure percentage after the first application. CONCLUSIONS: Cryopreserved human amniotic stem cell grafts can aid in the decreasing the time to closure of various types of lower extremity ulcerations. The therapy is a clinically viable option for physicians to consider when formulating a treatment plan for a patient with an ulcer.

Management of a chronic radiation necrosis wound with lyopreserved placental membrane containing viable cells

“…One proprietary cryopreservation method developed by Osiris Therapeutics results in high cell viability within the preserved placental membrane and is a commercially available cryopreserved placental membrane product containing viable cells . Cryopreserved placental membrane (vCPM) retains the components of fresh placental membrane, and its clinical effectiveness has been demonstrated in various trials with hard‐to‐treat wounds using vCPM plus standard of care …”

“…Also in 2016, a retrospective review of five actively smoking diabetics with six nonhealing ulcers and peripheral arterial disease (PAD) who received serial applications of vCPM reported positive outcomes, as all patients achieved complete wound closure . Further, Anselmo et al showed positive clinical outcomes with vCPM in the treatment of three chronic wounds that had previously failed standard wound care treatments. These patients also had significant comorbidities including chronic heart failure, diabetes, peripheral vascular disease, and venous insufficiency.…”

“…15,16 Cryopreserved placental membrane (vCPM) retains the components of fresh placental membrane, and its clinical effectiveness has been demonstrated in various trials with hard-to-treat wounds using vCPM plus standard of care. [20][21][22][23] In 2016, Frykberg et al demonstrated positive clinical outcomes in the treatment of complex diabetic foot ulcers (DFU) with vCPM. This patient population had significant comorbidities such as heart disease, kidney disease, and previous partial foot amputations.…”

Surgical Reconstruction of Stage 3 and 4 Pressure Injuries: A Literature Review and Proposed Algorithm from an Interprofessional Working Group

“…Such bioscaffolds commonly augment standard wound management of PIs (Table 1). [70][71][72][73][74][75][76][77][78][79][80][81][82][83][84] They are typically reapplied weekly to heal via secondary intention. When used with NPWT, the inclusion of a bioscaffold as part of standard wound management improves healing outcomes relative to NPWT alone in stage 4 PIs.…”

Strategies and challenges in the treatment of chronic venous leg ulcers

“…A retrospective review describes patients with chronic wounds that had failed standard of care treatments for more than 4 wk and were subsequently treated with weekly use of vCHPM grafts. All ulcers reached full closure in 4-5 wk with no complication[ 103 ]. After using hVWM of cryopreserved placental tissue, 53% (16/30) of CVLUs refractory to standard therapy healed completely.…”